ED
RCKT icon

Exane Derivatives’s Rocket Pharmaceuticals RCKT Stock Holding History

Exane Derivatives’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,240
Closed -$45.2K – 737
2020
Q1 		$45.2K Buy
+3,240
New +$64.2K 0.01% 359

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Exane Derivatives's RCKT Position: Q2 2020 in Review

Exane Derivatives sold out of Rocket Pharmaceuticals (RCKT) in Q2 2020, closing a stake of 3,240 shares — an estimated $45.2K sold.

Exane Derivatives first reported a position in RCKT in Q1 2020 and held it in 1 quarter. The position peaked at $45.2K in Q1 2020. 119 funds tracked by Wall St. Rank hold RCKT as of Q2 2020.

  • Exane Derivatives reported no remaining Rocket Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Exane Derivatives sold 3,240 Rocket Pharmaceuticals shares in Q2 2020, an estimated $45.2K.
  • Exane Derivatives first reported a position in Rocket Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Exane Derivatives's Rocket Pharmaceuticals position peaked at $45.2K in Q1 2020.
  • 119 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2020.

Based on Exane Derivatives's 13F filing for Q2 2020, filed 10 Jul 2020.